Similarly, the PRMT5 gene has been implicated in the development of chemoresistance; conversely, its inhibition renders pancreatic cancer cells more susceptible to gemcitabine, a commonly used first‐ or second‐line chemotherapeutic agent [249]. The gene discussed is PRMT5; the disease is familial pancreatic carcinoma.